Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01697969
Other study ID # M-12-047
Secondary ID
Status Completed
Phase Phase 4
First received September 27, 2012
Last updated July 30, 2014
Start date September 2012
Est. completion date July 2013

Study information

Verified date July 2014
Source Alcon Research
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to descriptively evaluate the corneal structures of allergic conjunctivitis patients.


Description:

Heidelberg Retina Tomograph (HRT) will be used to descriptively evaluate the corneal structures and assess the immune cell status of allergic conjunctivitis patients pre- and post-treatment with olopatadine 0.2% in relation to a normative database.


Recruitment information / eligibility

Status Completed
Enrollment 17
Est. completion date July 2013
Est. primary completion date July 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Read, sign, and date an Ethics Committee reviewed and approved informed consent form.

- Females of childbearing potential who:

- Are not breast-feeding;

- Do not intend to become pregnant for the duration of the study;

- Are using adequate birth control methods and agree to continue for the duration of the study.

- Able to read, understand and answer questions by investigator.

- Willing and able to attend all required study visits and follow directions as stipulated by the protocol and investigator.

- History of allergic conjunctivitis (within the past 12 months) and active signs and symptoms of ocular allergies for which treatment is necessary, in the opinion of the investigator.

- Visual acuity correctable to 20/30 (Snellen) or better in each eye at distance with or without glasses correction.

- Ocular health within normal limits as determined by the investigator.

- No contact lens wear 14 days prior to enrollment and willing to not wear contact lenses for the duration of the study.

- Willing to follow a 14-day washout period due to contraindicated medication use, if deemed necessary by investigator.

- Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

- Contraindications or hypersensitivity to the use of the test article or its components.

- Inability or unwillingness to follow all study instructions and complete study visits as required.

- Only one sighted eye or visual acuity not correctable to 20/30 (Snellen) in both eyes at the Screening Visit.

- Ocular trauma within 6 months prior to Visit 1 in either eye.

- Any ocular surgical intervention within six months prior to Visit 1 or anticipation of ocular surgery during the study.

- Presumed or actual ocular infection within 30 days prior to Visit 1.

- Any severe or serious ocular condition or significant illness.

- Any abnormal slit-lamp findings at the time of the Screening Visit.

- Contact lens wear within 14 days prior to the study start and unwillingness to undergo a wash-out period of 14 days; unwilling to not wear contact lenses for the duration of the study.

- Use of over-the-counter (OTC) ocular medications within the past 14 days unless willing to follow wash out period.

- Use of topical or systemic ocular medications requiring longer than a two-week washout period.

- Participation in any other investigational study in the 30-day period before entry into this study (i.e., Visit 1) or concomitantly with this study.

- Women who are pregnant, nursing, or of childbearing potential not utilizing adequate birth control measures.

- Other protocol-defined exclusion criteria may apply.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label


Intervention

Drug:
Olopatadine hydrochloride ophthalmic solution, 0.2%


Locations

Country Name City State
United States University of Iowa Iowa City Iowa

Sponsors (1)

Lead Sponsor Collaborator
Alcon Research

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patient-Assessed Ocular Itching The patient rated the severity of ocular itching using a predetermined 0-4 scale, where 0=none and 4=severe itching with irresistible urge to rub. Each eye was rated separately. A 2-week washout period from prior allergy medication (if applicable) preceded the baseline assessment. Baseline (Day 1), Day 14 No
See also
  Status Clinical Trial Phase
Completed NCT03660878 - A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Phase 1/Phase 2
Completed NCT03682965 - Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study Phase 2
Completed NCT01685242 - A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle Phase 3
Completed NCT01439815 - An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo Phase 4
Completed NCT01294969 - Patient Perception Study for AL-4943A Phase 4
Completed NCT01471184 - The Effects of Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops Compared to Placebo Phase 1
Completed NCT00609128 - Effect of Olopatadine on Allergic Tear Mediators N/A
Recruiting NCT05969236 - A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults Phase 1
Active, not recruiting NCT04619017 - Airway Immune Response to Allergens (Use Lay Language Here) Phase 1
Not yet recruiting NCT01012752 - A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts Phase 3
Completed NCT01754766 - AGN-229666 for the Treatment of Allergic Conjunctivitis Phase 2
Completed NCT01698814 - A Six-Week Safety Study of an Investigational Ophthalmic Solution Phase 3
Completed NCT01443442 - Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis Phase 4
Completed NCT01203540 - Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Phase 4
Completed NCT00987272 - Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects Phase 3
Completed NCT00769886 - Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis. Phase 3
Completed NCT00569777 - Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers Phase 3
Completed NCT00586664 - Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis Phase 3
Completed NCT00534794 - Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis Phase 4
Completed NCT00586625 - Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers Phase 3